Head and Neck Cancer

PV QA 2 - Poster Viewing Q&A 2

MO_23_2556 - Risk-Based Optimization of Intensity-Modulated Radiation Therapy Guideline for Post-Operative Oral Cavity Cancer

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Risk-Based Optimization of Intensity-Modulated Radiation Therapy Guideline for Post-Operative Oral Cavity Cancer
K. Y. Dai, Y. J. Chen, Y. M. Huang, J. C. H. Chen, Y. S. Chen, and S. Liu; Department of Radiation Oncology, MacKay Memorial Hospital, Taipei, Taiwan

Purpose/Objective(s): To optimize previously established national intensity-modulated radiation therapy (IMRT) guideline for post-operative oral cavity squamous cell carcinoma (OSCC) in 2008, the follow-up results focusing on pattern and risk of failure were analyzed.

Materials/Methods: Patients with OSCC treated with primary curative-intent surgery followed by postoperative IMRT according to the guideline with or without concurrent chemotherapy in our institute from 2010 to 2014 were retrospectively analyzed. Kaplan-Meier, univariate (UVA), and multivariate (MVA) Cox proportional hazard regression analyses were performed to identify predictors for locoregional control (LRC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). Locoregional recurrences (LRR) were reconstructed on the treatment planning computed tomography images by deformable image co-registration. Recurrences were classified as in-field, marginal or out-of-field if >95%, 20-95%, and <20% of the recurrence volume was within the 95% of the prescribed isodose, respectively.

Results: A total of 180 patients were enrolled in this study with a median follow-up of 49.6 months (range, 4.4-91.5 months). Among these patients, 133 (73.9%) remained disease-free during the follow-up period. There were 30 (16.7%) patients with LRR, 25 (13.9%) with distant metastasis, and 29 (16.1%) with second primary cancers. The 5-year LRC, DMFS, DFS, and OS were 82.6%, 73.3%, 67.6%, and 75.4%, respectively. On UVA, extracapsular extension (ECE) was the only factor significantly associated with poorer LRC (hazard ration, 2.49; 95% CI, 1.14-5.41; P = .022). On MVA, only pN2-3 was associated with worse DMFS (HR, 2.29; 95% CI, 1.02-5.15; P = .046), DFS (HR, 2.57; 95% CI, 1.18-5.56; P = .017), and OS (HR, 2.90; 95% CI, 1.13-7.45; P = .027). Of the 30 patients with LRR, 22 failed at the primary tumor site, 3 at the regional lymph nodes, and 5 at both the primary and lymph node areas. There were 28 LRR in high-risk planning target volume (PTV), 6 in intermediate-risk PTV, and 1 in low-risk PTV. Most LRR were in-field failures, except 11 marginal failures in high-risk PTV, and 1 in intermediate-risk PTV. Most common marginal failures occurred in infratemporal fossa (n=6) and ipsilateral parotid gland (n=4), all of which belonged to primary cancers originating from the buccal and gingival mucosa. Two out-of-field failures were noted over level VI neck and skin of the ipsilateral neck. The median time to LRR was 9.9 months (range, 2.0-68.2 months).

Conclusion: The 5-year follow-up outcome of previous IMRT guideline for postoperative OSCC might be feasible for good LRC and OS. Factors such as ECE and pN2-3 warrant further consideration for intensified adjuvant therapy. The marginal recurrence rates in infratemporal fossa and ipsilateral parotid gland were relatively high in buccal and gingival cancers, indicating a need for more generous margin coverage of related spreading routes to further optimize the guideline.

Author Disclosure: K. Dai: None. Y. Chen: None. Y. Huang: None. J.C. Chen: None.

Send Email for Kun-Yao Dai


Assets

MO_23_2556 - Risk-Based Optimization of Intensity-Modulated Radiation Therapy Guideline for Post-Operative Oral Cavity Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Risk-Based Optimization of Intensity-Modulated Radiation Therapy Guideline for Post-Operative Oral Cavity Cancer